Precision oncology diagnostics and pipeline readouts moved in tandem. A nanoparticle-enabled blood proteomics test can measure tumor hypoxia in bladder cancer, track it during radiotherapy, and predict who benefits from hypoxia-modifying treatment, according to a bladder cancer study. In liver cancer, investigators reported that tumor invasion grading in patients undergoing conversion therapy strongly predicts recurrence and survival, using a multicenter dataset where initially unresectable hepatocellular carcinoma becomes operable after tyrosine kinase inhibitors and anti-PD-1 antibodies. Separately, a molecular atlas of intra-tumor evolution in EGFR-mutant lung cancer mapped distinct stages of microenvironment remodeling as patients develop resistance to sequential EGFR-targeted therapies, reinforcing the need to match therapy to evolving tumor states. Taken together, the studies support a pipeline direction toward dynamic biomarkers—hypoxia, invasion grading, and spatial multi-omics—to improve selection and sequencing.